March 1, 2022REGENXBIO Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Operational Highlights
February 22, 2022REGENXBIO to Host Conference Call on March 1 to Discuss Fourth Quarter and Full-Year 2021 Financial Results and Recent Operational Highlights
February 12, 2022Suprachoroidal Delivery of RGX-314 for Diabetic Retinopathy Without CI-DME: Results from the Phase II ALTITUDE™ StudyMichael Klufas, M.D., Retina Service, Wills Eye Hospital, Assistant Professor of Ophthalmology, Thomas Jefferson University
February 9, 2022RGX-111 Gene Therapy for the Treatment of Severe Mucopolysaccharidosis Type I (MPS I): Interim Analysis of Data from the First in Human StudyRaymond Wang, M.D., Division of Metabolic Disorders, CHOC Children's Hospital, Department of Pediatrics, University of California, Irvine, CA
February 9, 2022RGX-121 Gene Therapy for the Treatment of Severe Mucopolysaccharidosis Type II (MPS II): Interim Analysis of Data from the First in Human StudyRoberto Giugliani, M.D., Ph.D., Presenter title: Professor, Department of Genetics, UFRGS, Medical Genetics Service, HCPA, Porto Alegre, Brazil
